Dr. Luis Raez speaks to ecancer about adjuvant treatment for NSCLC.

He talks about the lack of breakthroughs in this area, the introduction of TKIs, and some the more important trials that have existed up until now.

Dr Raez then explains the ADAURA trial, using osimertinib, and why this is such a big step forwards to adjuvant therapy.